554 related articles for article (PubMed ID: 26414147)
1. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
[TBL] [Abstract][Full Text] [Related]
2. Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.
Castle PE; Wheeler CM; Campos NG; Sy S; Burger EA; Kim JJ;
Prev Med; 2018 Jun; 111():177-179. PubMed ID: 29548787
[TBL] [Abstract][Full Text] [Related]
3. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
Kim JJ; Ortendahl J; Goldie SJ
Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455
[TBL] [Abstract][Full Text] [Related]
5. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
6. The value of improving failures within a cervical cancer screening program: an example from Norway.
Burger EA; Kim JJ
Int J Cancer; 2014 Oct; 135(8):1931-9. PubMed ID: 24615416
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
van Rosmalen J; de Kok IM; van Ballegooijen M
BJOG; 2012 May; 119(6):699-709. PubMed ID: 22251259
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
[TBL] [Abstract][Full Text] [Related]
10. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Holmes J; Hemmett L; Garfield S
Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
Munshi VN; Perkins RB; Sy S; Kim JJ
Am J Obstet Gynecol; 2022 Feb; 226(2):228.e1-228.e9. PubMed ID: 34547295
[TBL] [Abstract][Full Text] [Related]
14. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
[TBL] [Abstract][Full Text] [Related]
15. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y
BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
17. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.
Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I
BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon.
Sharma M; Seoud M; Kim JJ
Vaccine; 2017 Jan; 35(4):564-569. PubMed ID: 28017434
[TBL] [Abstract][Full Text] [Related]
20. Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.
Pedersen K; Burger EA; Sy S; Kristiansen IS; Kim JJ
Gynecol Oncol; 2016 Nov; 143(2):326-333. PubMed ID: 27542966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
